No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin
Secondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the risk of emergence of colistin resistance in the respiratory tract during secondary IC prophylaxis. We conducted a prospective, single-centre, observational study of all adult patients who underwent LT between 1 July 2018 and 30 June 2019. IC was started and continued for at least 90 days for <i>P. aeruginosa</i> or ESBL-PE pneumonia. During the 90 days following LT, all respiratory samples were routinely tested for the presence of GNB of reduced susceptibility to colistin. Twenty-seven (38.6%) of the 70 included patients received IC. Among the 867 respiratory samples tested, IC did not promote the emergence of bacterial species with natural or acquired resistance to colistin (incidence-rate ratio of 0.21 [0.03-1.58], <i>p</i> = 0.13 and 1.68 [0.55-5.12], <i>p</i> = 0.37, respectively). Our study suggests no association between the use of IC and an increased risk of colistin resistance in the respiratory tract within 90 days of LT.
Authors
- Charles Burdet (ORCID: https://orcid.org/0000-0003-4138-0794)
- Enora Atchade (ORCID: https://orcid.org/0000-0003-2726-106X)
- Brice Lortat‐Jacob (ORCID: https://orcid.org/0000-0001-7182-3678)
- Alexy Tran‐Dinh (ORCID: https://orcid.org/0000-0003-4361-5104)
- Marie Petitjean (ORCID: https://orcid.org/0000-0003-0397-2051)
- Marina Esposito‐Farèse
- Signara Gueye (ORCID: https://orcid.org/0000-0003-2094-030X)
- Nathalie Grall
- Vincent Bunel (ORCID: https://orcid.org/0000-0002-5080-6331)
- Philippe Montravers (ORCID: https://orcid.org/0000-0002-3422-5705)
- Maksud Assadi
- Jonathan Messika (ORCID: https://orcid.org/0000-0003-2123-3527)
- Érick Denamur (ORCID: https://orcid.org/0000-0002-7860-1717)
- Pierre Mordant (ORCID: https://orcid.org/0000-0001-5716-4848)
- Sébastien Tanaka (ORCID: https://orcid.org/0000-0003-3858-9319)
- Yves Castier (ORCID: https://orcid.org/0009-0007-0170-1668)
- Hervé Mal (ORCID: https://orcid.org/0000-0002-5951-436X)
- Laurence Armand-Lefevre
- B Garnier
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- University of Reunion Island (RE)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Laboratoire de Recherche Vasculaire Translationnelle (FR)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- Transplant International
- Published
- 2025-01-23
- DOI
- https://doi.org/10.3389/ti.2024.13545
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00